Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT07049224
Recruiting Not applicable

The Effectiveness of a Diet With Beef as Key Protein Component Versus a Plant-Based Diet to Support Integrated Muscle Protein Synthesis Rates in Healthy Older Individuals

NCT07049224 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2024-12-09
Last updated
2025-07-03

Condition(s) studied

Muscle Protein Synthetic Response to Protein

Investigational drug(s) / intervention(s)

Meat dietPlant diet

Meat diet: Participants will be subjected to a 10-day diet containing meat and animal products. During the interventional period participants will perform unilateral lower limb resistance exercise.

Plant diet: Participants will be subjected to a 10-day diet containing plant products. During the interventional period participants will perform unilateral lower limb resistance exercise.

Study summary

Muscles are composed out of proteins. These proteins in turn are composed out of smaller building blocks, called amino acids. By consuming a sufficient amount of dietary protein, a sufficient amount of amino acids become available to build new muscle proteins. The body's ability to build these new muscle proteins is of great importance to maintain muscle strength and function.

Previous research suggests that a meal containing proteins from meat results in a better stimulation of the body's ability to build muscle proteins, when compared to a meal containing only plant-based proteins. However, these previous studies have only been performed following the ingestion of a single meal. As a result it is currently unknown how the muscles respond to a more prolonged ingestion of a diet containing animal/meat products, in comparison to a plant-based diet. Therefore, this study aims to investigate how fast new muscle proteins are being build when consuming a diet containing animal/meat products, in comparison to a plant-based (vegan) diet.

Eligibility

Sex
ALL
Min age
65 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female sex * Aged between 65 and 85 y inclusive * BMI between 18.5 and 30 kg/m2 inclusive Exclusion Criteria: * Not willing to consume meat/animal-based products during the study period * Any food allergies (e.g. milk, gluten, etc.) * Participating currently or in the 3 months prior to the study in a structured progressive exercise program. * Smoking * History of cardiovascular, respiratory, gastrointestinal, urogenital, neurological, psychiatric, dermatologic, musculoskeletal, metabolic, endocrine, haematological, immunologic disorders, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol, interfere with the execution of the experiment, or potential influence the study outcomes (to be decided by the study team and responsible physician) * Diagnosed with phenylketonuria (PKU) * Donated full blood 3 months prior to test day * Use of any medications that interferes with study participation and/or outcomes (i.e. corticosteroids, non-steroidal anti-inflammatories, gastric acid suppressing medication) as assessed by the study team and responsible medical doctor. * Use of DOAC, vitamin-K-antagonist, or multiple anticoagulants * Fasting blood glucose \>7 mmol/L

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maastricht University Medical Centre+ Maastricht Limburg Recruiting

More Maastricht University Medical Center trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07049224 on ClinicalTrials.gov ↗ ← All trials in the Netherlands